INO Inovio Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INO

Price (delayed)

$10.33

Market cap

$241.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.09

Enterprise value

$257.31M

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
INO's EPS has surged by 57% year-on-year and by 20% since the previous quarter
INO's net income has surged by 52% year-on-year and by 18% since the previous quarter
INO's quick ratio is up by 27% year-on-year but it is down by 11% since the previous quarter
INO's revenue has dropped by 92% year-on-year and by 2.6% since the previous quarter
The gross profit has dropped by 92% year-on-year and by 2.6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inovio.com
Peers: PFE JNJ ARWR NVS

Key stats

What are the main financial stats of INO
Market
Shares outstanding
23.37M
Market cap
$241.42M
Enterprise value
$257.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
275.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
309.27
Earnings
Revenue
$832,010
EBIT
-$133.89M
EBITDA
-$130.39M
Free cash flow
-$118.47M
Per share
EPS
-$6.09
Free cash flow per share
-$5.34
Book value per share
$5.16
Revenue per share
$0.04
TBVPS
$7.71
Balance sheet
Total assets
$170.95M
Total liabilities
$53.6M
Debt
$30.21M
Equity
$117.35M
Working capital
$110.54M
Liquidity
Debt to equity
0.26
Current ratio
3.6
Quick ratio
3.47
Net debt/EBITDA
-0.12
Margins
EBITDA margin
-15,671.8%
Gross margin
100%
Net margin
-16,239.9%
Operating margin
-17,300.3%
Efficiency
Return on assets
-62.6%
Return on equity
-86.6%
Return on invested capital
-81.8%
Return on capital employed
-104.3%
Return on sales
-16,092.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-0.39%
1 week
-6.68%
1 month
-11.1%
1 year
-0.04%
YTD
68.79%
QTD
-25.58%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$832,010
Gross profit
$832,010
Operating income
-$143.94M
Net income
-$135.12M
Gross margin
100%
Net margin
-16,239.9%
INO's revenue has dropped by 92% year-on-year and by 2.6% since the previous quarter
The gross profit has dropped by 92% year-on-year and by 2.6% since the previous quarter
INO's net income has surged by 52% year-on-year and by 18% since the previous quarter
INO's operating income is up by 46% YoY and by 17% QoQ

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
2
P/S
275.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
309.27
INO's EPS has surged by 57% year-on-year and by 20% since the previous quarter
The stock's price to book (P/B) is 123% more than its last 4 quarters average of 0.9 but 77% less than its 5-year quarterly average of 8.9
The equity has contracted by 47% YoY and by 15% from the previous quarter
INO's revenue has dropped by 92% year-on-year and by 2.6% since the previous quarter
The P/S is 7% lower than the 5-year quarterly average of 295.7

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's return on sales is up by 16% since the previous quarter
The company's return on invested capital rose by 14% YoY and by 8% QoQ
INO's ROE is up by 12% YoY and by 4.1% from the previous quarter
INO's return on assets is up by 8% year-on-year

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 58% YoY and by 2.4% QoQ
The total assets has dropped by 51% year-on-year and by 11% since the previous quarter
Inovio Pharmaceuticals's debt is 74% lower than its equity
The debt to equity has soared by 86% YoY and by 18% from the previous quarter
The equity has contracted by 47% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.